Zepbound Explained — The New Weight Loss Drug cover art

Zepbound Explained — The New Weight Loss Drug

Zepbound Explained — The New Weight Loss Drug

By: Inception Point Ai
Listen for free

About this listen

 Eli Lilly's Zepbound delivers up to 21% weight loss through a groundbreaking dual-hormone mechanism that's reshaping obesity treatment. Join host Julia Cartwright as she decodes the science, clinical trial results, and real-world access barriers behind this revolutionary injection. Each episode stands alone, exploring a different facet of medicine's newest metabolic game-changer.

For more content like this, visit QuietPlease.ai

This show includes AI-generated content.Copyright 2025 Inception Point Ai Hygiene & Healthy Living Physical Illness & Disease
Episodes
  • Zepbound Explained — Navigate the new frontier of weight loss with Julia Cartwright

    Zepbound Explained — Navigate the new frontier of weight loss with Julia Cartwright
    Apr 7 2026
    Join host Julia Cartwright as she breaks down Zepbound, the groundbreaking weight loss drug revolutionizing obesity treatment with its dual-hormone approach. Discover how this weekly injection works, who qualifies, and what clinical trials reveal—explained in plain English. Get the straight facts to make informed decisions about this weight management breakthrough.

    Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch just a slice of our AI hosts in action on Instagram at instagram.com/claredelish and YouTube at youtube.com/@DIYHOMEGARDENTV

    This content was created in partnership and with the help of Artificial Intelligence AI

    This episode includes AI-generated content.
    Show More Show Less
    1 min
  • Zepbound Explained — The New Weight Loss Drug - The Numbers Don't Lie

    Zepbound Explained — The New Weight Loss Drug - The Numbers Don't Lie
    Apr 7 2026
    Join AI host Julia Cartwright as she breaks down the groundbreaking SURMOUNT clinical trials for tirzepatide (Zepbound). We cover the landmark data showing average weight loss of 21% at the highest dose, with 57% of participants losing over 20% of body weight—results previously seen only with bariatric surgery, fundamentally reshaping obesity medicine's possibilities.

    Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch just a slice of our AI hosts in action on Instagram at instagram.com/claredelish and YouTube at youtube.com/@DIYHOMEGARDENTV

    This content was created in partnership and with the help of Artificial Intelligence AI

    This episode includes AI-generated content.
    Show More Show Less
    23 mins
  • Zepbound Explained — The New Weight Loss Drug - Who Gets the Shot? Eligibility & Access

    Zepbound Explained — The New Weight Loss Drug - Who Gets the Shot? Eligibility & Access
    Apr 7 2026
    Julia Cartwright explores who qualifies for Zepbound, the GLP-1 weight loss medication showing 15-21% body weight reduction in trials. Learn FDA eligibility criteria, BMI thresholds, required comorbidities, and how to navigate the complex insurance prior authorization process that stands between patients and this transformative treatment option.

    Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch just a slice of our AI hosts in action on Instagram at instagram.com/claredelish and YouTube at youtube.com/@DIYHOMEGARDENTV

    This content was created in partnership and with the help of Artificial Intelligence AI

    This episode includes AI-generated content.
    Show More Show Less
    22 mins
No reviews yet